Assessment of Supportive Care Practices in Adult Patients Receiving Bispecific Antibodies for Hematological Malignancies

Document Type

Conference Proceeding

Publication Date

3-6-2026

Publication Title

Am J Health Syst Pharm

Keywords

anakinra, bispecific antibody, corticosteroid, tocilizumab, adult, antimicrobial activity, cohort analysis, conference abstract, cytokine release syndrome, electronic health record, female, Food and Drug Administration, hematologic malignancy, hospitalization, human, lymphoma, major clinical study, morbidity, neurotoxicity, observational study, opportunistic infection, pharmacist, premedication, prophylaxis, retrospective study, side effect, T lymphocyte, therapy

Abstract

Purpose: Hematological malignancies, including myeloma, lymphoma, and leukemia, contribute significantly to morbidity and mortality, especially in relapsed or refractory cases. Bispecific antibodies (BsAbs), which target both T cells and tumor antigens, have improved outcomes but carry risks of severe toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and opportunistic infections. This study aims to assess adherence to a standardized supportive care protocol for BsAb-related toxicities across a large health system. Findings will offer real-world insight into toxicity prophylaxis, recognition, and management practices in both the inpatient and outpatient settings. Methods: This retrospective, observational study will evaluate adult patients with hematological malignancies who received at least one dose of an FDA-approved BsAb during hospitalization or at an affiliated oncology clinic/infusion center between November 1st, 2022, and August 31st, 2025. The institutional protocol, implemented in March 2024, outlines strategies for prophylaxis, monitoring, recognition, grading, and management of BsAb-associated toxicities. Electronic health records (Cerner eCare® and OncoEMR®) will be reviewed to determine adherence to premedication strategies, prophylactic antimicrobial use, CRS/ICANS screening and grading (ASTCT and ICE tools), timely interventions (i.e., tocilizumab, corticosteroids, anakinra), and documentation by nurses and providers. Additional variables include use of consult services, escalation to inpatient/intensive care monitoring, and management of opportunistic infections. Data will be coded as binary (yes/no) to calculate adherence rates. Descriptive statistics will characterize adherence patterns and results will be used to identify operational and educational opportunities to improve supportive care practices. Results: Results of this study to be presented at American Society of Health-System Pharmacists Midyear Clinical Meeting 2025. Conclusion: Conclusion of this study to be presented at American Society of Health-System Pharmacists Midyear Clinical Meeting 2025.

Volume

83

Issue

Supplement_2

First Page

S809

Find It @ Sladen

Share

COinS